Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00070655
Other study ID # EFC5134
Secondary ID SR34006
Status Completed
Phase Phase 3
First received October 6, 2003
Last updated April 5, 2011
Start date September 2003
Est. completion date March 2006

Study information

Verified date April 2011
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This trial will include patients who have a heart condition called atrial fibrillation. Atrial fibrillation is an abnormal rhythm (irregular beat) in the heart. Patients with atrial fibrillation have an increased chance for a blood clot to form in the heart and move to other blood vessels in the body and cause obstruction. This obstruction may damage tissue. For example, a blood clot plugging a vessel in the brain could cause a stroke. Therefore, patients with atrial fibrillation may be given anticoagulant (blood-thinning) tablets such as warfarin or acenocoumarol.

The purpose of this study is to compare the safety and effectiveness of a new injectable anticoagulant drug that is administered once weekly, SR34006 with warfarin or acenocoumarol tablets.

Assignment to either SR34006 Injection or vitamin K antagonist (warfarin or acenocoumarol) tablets will be purely by chance and will be known by both patients and their doctors.


Recruitment information / eligibility

Status Completed
Enrollment 4673
Est. completion date March 2006
Est. primary completion date March 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- ECG-documented atrial fibrillation (AF) and an indication for long-term vitamin K antagonist (VKA) therapy based on the presence of at least one of the following risk factors:

1. previous ischemic stroke, transient ischemic attack (TIA) or systemic embolism

2. hypertension requiring drug treatment

3. left ventricular dysfunction (left ventricular ejection fraction <45% or symptomatic congestive heart failure)

4. age >75 years

5. age between 65-75 years plus diabetes mellitus, or

6. age between 65-75 years plus symptomatic coronary artery disease (previous myocardial infarction (MI) or angina pectoris)

- Written informed consent

Exclusion Criteria:

- Legal lower age limitations (country specific)

- Indication for VKA other than AF, including prosthetic heart valves, venous thromboembolism, and planned cardioversion

- Transient AF caused by a reversible disorder

- Active bleeding or high risk of bleeding

- Recent (<15 days) or anticipated invasive procedures with potential for uncontrolled bleeding, including major surgery

- Participation in another pharmacotherapeutic study within the prior 30 days

- Creatinine clearance <10 mL/min, severe hepatic disease, or bacterial endocarditis

- Uncontrolled hypertension: systolic blood pressure > 180 mm Hg and/or diastolic blood pressure > 110 mm Hg

- Pregnancy or childbearing potential without proper contraceptive measures

- Breastfeeding

- Any other contraindication listed in the labeling of warfarin or acenocoumarol

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
SR34006 (idraparinux sodium) Injection

vitamin K antagonist (warfarin or acenocoumarol) tablets


Locations

Country Name City State
Australia Concord Repartiation General Hospital Concord
Canada Cardiology Consultant's Group Calgary Alberta
Canada Foothills Medical Centre Calgary Alberta
Canada Heart Health Institute Calgary Alberta
Canada University of Calgary Calgary Alberta
Canada Dr. M.P.J. Senaratne Professional Corporation Edmonton Alberta
Canada Moose Jaw Cardiac Centre Moose Jaw Saskatchewan
Canada West Coast Cardiology Research New Westminster British Columbia
Canada Royal University Hospital Saskatoon Saskatchewan
Canada Saskatoon Medical Specialists Saskatoon Saskatchewan
Canada Specialists Internal Medicine Saskatoon Saskatchewan
Canada Zoom International Inc. St. Jerome Quebec
Canada Health Care Corporation of St. John's Health Sciences Centre St. John's Newfoundland and Labrador
Canada Cardiac Arrhythmia Trials Victoria British Columbia
Canada Dr. Joesph J. Javier Yorkton Saskatchewan
Canada Yorkton Regional Health Centre Yorkton Saskatchewan
Italy A.O. "Instituti Ospitalieri di Cremona" Cremona
Italy Azienda Ospedaliera San Paolo Milano
Italy Azienda Ospedaliera di Parma Parma
Italy U.O. di Medicina Interna II Parma
Italy Centro Emostasi e Trombosi Rimini
Netherlands Academisch Ziekenhuis Maastricht Maastricht
United Kingdom University Hospital of Wales Cardiff
United Kingdom University of Glasgow Glasgow
United Kingdom Freeman Hospital Newscastle Upon Tyne
United Kingdom New Cross Hospital Wolverhampton
United States New Mexico Heart Institute, PA Albuquerque New Mexico
United States University of New Mexico Hospital Albuquerque New Mexico
United States Aurora Denver Cardiology Associates Aurora Colorado
United States Austin Heart, P.A. Austin Texas
United States Cardiology, P.C. Birmingham Alabama
United States Heart & Vascular Clinic/Advanced Medical Research Covington Louisiana
United States Cardiovascular Research Institute of Dallas, Inc./Cardiology and Internal Medicine Associates Dallas Texas
United States Denver Health and Hospital Authority Adult Medicine Clinic Denver Colorado
United States Denver Health and Hospital Authority Eastside Health Clinic Denver Colorado
United States Denver Health Medical Center Denver Colorado
United States Duke University Medical Center Durham North Carolina
United States Florida Arrhythmia Consultants Fort Lauderdale Florida
United States North Broward Hospital District Cardiovascular Research Institute Fort Lauderdale Florida
United States Office of Dr. Bowden, D.O. Healdsburg California
United States Oracle Research, a Division of: The Heart Center, P.C. Huntsville Alabama
United States Beacon Medical Research Indianapolis Indiana
United States Jacksonville Cardiovascular Clinic Jacksonville Florida
United States Jacksonville Center for Clinical Research Jacksonville Florida
United States The Clinic (Lake Charles Medical & Surgical Clinic) Lake Charles Louisiana
United States Jerry L. Pettis VA Medical Center Loma Linda California
United States Marshfield Clinic Marshfield Wisconsin
United States St. Joseph's Hospital Marshfield Wisconsin
United States Arizona Heart Institute Mesa Mesa Arizona
United States IMG Healthcare, LLC New Orleans Louisiana
United States Practice of James A. Underberg @ Murray Hill Medical Group New York New York
United States Kenneth W. Carr, M.D. Cardiology Oceanside California
United States Blackstone Cardiology Associates, P.C. Pawtucket Rhode Island
United States The Oregon Health and Science University Portland Oregon
United States McGuire VA Medical Center Richmond Virginia
United States LDS Hospital Salt Lake City Utah
United States Physicians Office Building (POB) Salt Lake City Utah
United States South Texas Cardiovascular Consultants San Antonio Texas
United States Richard A. Levy, M.D. San Francisco California
United States Cardiology Specialists of Orange County Santa Ana California
United States Cardiovascular Center of Sarasota Sarasota Florida
United States Swedish Medical Center Seattle Washington
United States Inland Cardiology Spokane Washington
United States Baystate Medical Center Springfield Massachusetts
United States Saguaro Clinical Research Tucson Arizona
United States Southern Arizona Veterans Affairs Health Care System Tucson Arizona
United States Wellington Green Family Practice Wellington Florida

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Denmark,  France,  Italy,  Netherlands,  New Zealand,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite of all strokes and non-CNS systemic embolism.
Secondary Separate components of the primary study outcome.
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A

External Links